Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 8, 2012

GenOway to Offer PhenoPro’s Mouse Model Phenotyping Services and Expertise

  • French firms genOway and PhenoPro established a strategic alliance through which genOway will exclusively distribute PhenoPro’s services and expertise in mouse model phenotyping and phenogenomics. Established in 2007, Institut Clinique de la Souris spin-out PhenoPro claims to have one of the most advanced and complete phenotyping platforms, founded on the phenotyping of over 800 genetically modified lines over the last six years.

    GenOway offers customized mouse models for the biopharma, chemical, agrochemical, and food industries, and for academic research. The firm says adding PhenoPro’s platform and expertise for customized phenotyping services will provide a more integrated offering for its clients.

    “We have developed a unique technological platform to provide scientists with the most adapted and innovative genetically modified models,” comments Alexandre Fraichard, genOway CEO. “We made the strategic decision to expand this offer to the phenotyping of created models. PhenoPro was the best potential partner since their technologies are well-recognized by the scientific community and we share the same strategy: to develop the most adapted customer services.”


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »